AP2008004713A0 - Improvements relating to anti-parasetic compositions - Google Patents

Improvements relating to anti-parasetic compositions

Info

Publication number
AP2008004713A0
AP2008004713A0 AP2008004713A AP2008004713A AP2008004713A0 AP 2008004713 A0 AP2008004713 A0 AP 2008004713A0 AP 2008004713 A AP2008004713 A AP 2008004713A AP 2008004713 A AP2008004713 A AP 2008004713A AP 2008004713 A0 AP2008004713 A0 AP 2008004713A0
Authority
AP
ARIPO
Prior art keywords
parasetic
compositions
improvements relating
relating
parasetic compositions
Prior art date
Application number
AP2008004713A
Other languages
English (en)
Inventor
David John Duncalf
Asha Hassan Essa
Alison Jayne Foster
Original Assignee
Unilever Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unilever Plc filed Critical Unilever Plc
Publication of AP2008004713A0 publication Critical patent/AP2008004713A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
    • A01N25/02—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests containing liquids as carriers, diluents or solvents
    • A01N25/04—Dispersions, emulsions, suspoemulsions, suspension concentrates or gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dentistry (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Environmental Sciences (AREA)
  • Plant Pathology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
AP2008004713A 2006-07-13 2007-06-29 Improvements relating to anti-parasetic compositions AP2008004713A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0613925.7A GB0613925D0 (en) 2006-07-13 2006-07-13 Improvements relating to nanodispersions
PCT/EP2007/056561 WO2008006713A2 (en) 2006-07-13 2007-06-29 Improvements relating to anti-parasitic compositions

Publications (1)

Publication Number Publication Date
AP2008004713A0 true AP2008004713A0 (en) 2008-12-31

Family

ID=36955583

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2008004713A AP2008004713A0 (en) 2006-07-13 2007-06-29 Improvements relating to anti-parasetic compositions

Country Status (17)

Country Link
US (10) US9060937B2 (enExample)
EP (8) EP2387992A1 (enExample)
JP (9) JP2009542762A (enExample)
CN (11) CN102631874A (enExample)
AP (1) AP2008004713A0 (enExample)
AR (4) AR061990A1 (enExample)
AU (9) AU2007271827B2 (enExample)
BR (8) BRPI0722376A2 (enExample)
CA (8) CA2659666A1 (enExample)
CL (4) CL2007002031A1 (enExample)
ES (2) ES2741124T3 (enExample)
GB (1) GB0613925D0 (enExample)
IL (2) IL195911A0 (enExample)
MX (2) MX2009000307A (enExample)
TW (1) TW200812694A (enExample)
WO (8) WO2008006716A2 (enExample)
ZA (7) ZA200900030B (enExample)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0501833D0 (en) * 2005-01-28 2005-03-09 Unilever Plc Carrier liquids and methods of production thereof
US20090130212A1 (en) * 2006-05-15 2009-05-21 Physical Pharmaceutica, Llc Composition and improved method for preparation of small particles
GB0613925D0 (en) * 2006-07-13 2006-08-23 Unilever Plc Improvements relating to nanodispersions
WO2008022651A1 (en) 2006-08-21 2008-02-28 Antoine Turzi Process and device for the preparation of platelet rich plasma for extemporaneous use and combination thereof with skin and bone cells
AR063704A1 (es) 2006-09-14 2009-02-11 Makhteshim Chem Works Ltd Nanoparticulas de pesticida obtenida obtenidas a partir de microemulsiones y nanoemulsiones
EP2124556B1 (en) 2006-10-09 2014-09-03 Charleston Laboratories, Inc. Pharmaceutical compositions
WO2009081283A2 (en) * 2007-06-18 2009-07-02 Combino Pharm, S.L. Aqueous formulations of acetaminophen for injection
EP2170313A2 (en) * 2007-06-18 2010-04-07 Combino Pharm, S.L. Aqueous formulations of acetaminophen for injection
AU2008303129B2 (en) * 2007-09-25 2013-08-01 Formulex Pharma Innovations Ltd. Compositions comprising lipophilic active compounds and method for their preparation
US8124126B2 (en) 2008-01-09 2012-02-28 Charleston Laboratories, Inc. Pharmaceutical compositions
TR200800634A2 (tr) * 2008-01-30 2009-02-23 Takka Sevgi̇ Uzatılmış salım sağlayan fluvastatin tablet.
CN102105136B (zh) * 2008-03-11 2014-11-26 蒂宝制药公司 包含非-阿片类止痛剂和阿片类止痛剂的组合的胃滞留型缓释剂型
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
CA2730199C (en) * 2008-07-11 2013-07-30 Nippon Soda Co., Ltd. Method of manufacture of sustained-release formulation composition
GB0814953D0 (en) * 2008-08-18 2008-09-24 Unilever Plc Improvements relating to nanodisperse compositions
EP3378310B1 (en) 2008-09-25 2021-08-04 Vive Crop Protection Inc. Methods to produce polymer nanoparticles and formulations of active ingredients
FR2938433B1 (fr) * 2008-11-19 2011-09-09 Francois Fauran Compositions pharmaceutiques utilisant l'inuline comme excipient de granulation
NZ593327A (en) * 2008-12-12 2014-11-28 Tim Tech Chemicals Ltd Compositions for the treatment of timber and other wood substrates
EP2243477A1 (de) 2009-04-22 2010-10-27 Fresenius Kabi Deutschland GmbH Paracetamol zur parenteralen Verabreichung
KR101374854B1 (ko) 2009-05-27 2014-03-19 주식회사 삼양바이오팜 생체이용률이 향상된 난용성 약물 함유 미립구 및 그 제조 방법
HUP0900376A2 (en) * 2009-06-19 2011-01-28 Nangenex Nanotechnologiai Zartkoerueen Muekoedoe Reszvenytarsasag Nanoparticulate candesartan cilexetil composition
HUP0900384A2 (en) * 2009-06-19 2011-01-28 Nangenex Nanotechnologiai Zartkoerueen Muekoedoe Reszvenytarsasag Nanoparticulate olmesartan medoxomil compositions
WO2010151080A2 (ko) * 2009-06-25 2010-12-29 진양제약 주식회사 카르복시로자탄을 함유하는 약학 조성물 및 이의 제조방법
EP2451274B1 (en) 2009-07-08 2017-10-04 Charleston Laboratories, Inc. Pharmaceutical compositions
AU2010286354A1 (en) * 2009-08-31 2012-04-19 Depomed, Inc. Gastric retentive pharmaceutical compositions for immediate and extended release of acetaminophen
JP5498769B2 (ja) * 2009-12-04 2014-05-21 花王株式会社 脂溶性薬物内包ナノ粒子の製造方法
US8597681B2 (en) 2009-12-22 2013-12-03 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
EP2536396B1 (en) 2010-02-16 2016-08-10 KRKA, D.D., Novo Mesto Process for the preparation of oral solid dosage forms comprising valsartan
CN106974316B (zh) 2010-03-29 2019-07-19 弗门尼舍有限公司 制备喷雾干燥产品的方法以及由该方法制备得到的喷雾干燥颗粒
GB201006038D0 (en) * 2010-04-12 2010-05-26 Unilever Plc Improvements relating to antiviral compositions
UA111167C2 (uk) * 2010-08-05 2016-04-11 ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі Пестицидні композиції мезорозмірних частинок з підсиленою дією
EP2624819A1 (en) 2010-10-05 2013-08-14 Iota NanoSolutions Limited Processes for preparing improved compositions
US8877221B2 (en) 2010-10-27 2014-11-04 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising calcium phosphate particles and statins and methods of using the same
US9107983B2 (en) 2010-10-27 2015-08-18 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising statins
WO2012082765A2 (en) 2010-12-16 2012-06-21 The United State Of America. As Represented By The Secretary Department Of Health And Human Services Methods for decreasing body weight and treating diabetes
CA2832611C (en) 2011-04-12 2019-05-14 Rigel Pharmaceuticals, Inc. Methods for inhibiting allograft rejection
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
US9050335B1 (en) 2011-05-17 2015-06-09 Mallinckrodt Llc Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US9308190B2 (en) 2011-06-06 2016-04-12 Warsaw Orthopedic, Inc. Methods and compositions to enhance bone growth comprising a statin
JP2013001771A (ja) * 2011-06-14 2013-01-07 Neos Co Ltd 液状カビ防除洗浄剤組成物
RU2469536C1 (ru) * 2011-06-16 2012-12-20 Государственное бюджетное учреждение Республики Башкортостан "Научно-исследовательский технологический институт гербицидов и регуляторов роста растений с опытно-экспериментальным производством Академии наук Республики Башкортостан" Фунгицидное средство и способ его получения
BR112013033239A2 (pt) 2011-06-22 2016-09-06 Vyome Biosciences pró-farmácos de conjugado baseado em atifungicos e antibacterianos
BR112014004139B1 (pt) 2011-08-23 2021-11-16 Vive Crop Protection Inc Formulação; e método de controle de insetos
GB201115079D0 (en) * 2011-08-31 2011-10-19 Iota Nanosolutions Ltd Method of preparing carrier liquids
GB201115635D0 (en) 2011-09-09 2011-10-26 Univ Liverpool Compositions of lopinavir and ritonavir
GB201115633D0 (en) 2011-09-09 2011-10-26 Univ Liverpool Compositions of efavirenz
GB201115634D0 (en) 2011-09-09 2011-10-26 Univ Liverpool Compositions of lopinavir
US8609684B2 (en) * 2011-12-12 2013-12-17 PruGen IP Holdings, Inc. Solubilization and bioavailability of acetaminophen
CN104080333B (zh) 2011-12-22 2017-06-23 维弗作物保护公司 嗜球果伞素配制品
MX374014B (es) * 2012-05-16 2020-07-24 Mewa Singh Composiciones farmaceuticas para la entrega de farmacos insolubles en agua.
WO2014011830A1 (en) 2012-07-12 2014-01-16 Mallinckrodt Llc Extended release, abuse deterrent pharmaceutical compositions
US20140073678A1 (en) * 2012-09-12 2014-03-13 Monosol Rx, Llc Anti-pain and anti-nausea and/or vomiting combinatorial compositions
CA2914583C (en) 2013-06-04 2019-06-18 Vyome Biosciences Pvt. Ltd. Coated particles and compositions comprising same
CA3042642A1 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
CA2928135A1 (en) 2013-10-21 2015-04-30 Salk Institute For Biological Studies Mutated fibroblast growth factor (fgf) 1 and methods of use
DK3069733T3 (da) * 2013-11-13 2022-11-14 National Defense Education And Res Foundation Ny acetaminophenforbindelsessammensætning uden bivirkninger for leveren
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
WO2015134920A1 (en) 2014-03-07 2015-09-11 The Arizona Board Of Regents On Behalf Of The University Of Arizona Non-narcotic crmp2 peptides targeting sodium channels for chronic pain
EP2952208A1 (en) * 2014-06-04 2015-12-09 Universidade de Santiago de Compostela Hydroalcoholic system for nail treatment
HUE061928T2 (hu) 2014-06-11 2023-09-28 SpecGx LLC Különbözõ oldódási profillal rendelkezõ porlasztva szárított készítmények és elõállításukhoz szükséges eljárások
CN104042626A (zh) * 2014-07-01 2014-09-17 李绍明 杀菌抑菌剂
EP3169315B1 (en) 2014-07-17 2020-06-24 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
WO2016064873A1 (en) 2014-10-20 2016-04-28 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
WO2016105598A1 (en) * 2014-12-23 2016-06-30 Dow Global Technologies Llc Treated porous material
EP3247334A1 (en) * 2015-01-20 2017-11-29 Merck Patent GmbH Solid dispersions of compounds using polyvinyl alcohol as a carrier polymer
CN104798772B (zh) * 2015-03-13 2017-05-24 中国农业科学院农业环境与可持续发展研究所 一种农药纳米固体分散体及其制备方法
HK1254670A1 (zh) 2015-07-02 2019-07-26 Civitas Therapeutics, Inc. 曲普坦粉末用於肺部给药
US10206904B2 (en) 2015-07-17 2019-02-19 The Board Of Regents Of The University Of Oklahoma Licofelone derivatives and methods of use
CN105145553A (zh) * 2015-10-12 2015-12-16 广西田园生化股份有限公司 一种难溶农药的固体分散体组合物
PL3410851T3 (pl) * 2016-02-02 2020-12-28 Evonik Operations Gmbh Proszkowe formulacje substancji powierzchniowo czynnych na nośnikach stałych, rozpuszczalnych w wodzie, sposób ich wytwarzania i zastosowania
EP3423041A4 (en) 2016-03-04 2019-09-11 Charleston Laboratories, Inc. PHARMACEUTICAL COMPOSITIONS
EP3471697B1 (en) 2016-06-16 2024-09-04 The University of Liverpool Chemical composition
RU2619249C1 (ru) * 2016-11-07 2017-05-12 Федеральное государственное бюджетное учреждение науки Институт химии твердого тела и механохимии Сибирского отделения Российской академии наук (ИХТТМ СО РАН) Композиция для протравливания семян и способ её получения
WO2018160772A1 (en) 2017-02-28 2018-09-07 The United State Of America, As Represented By The Secretary, Department Of Health & Human Services Method of treating obesity, insulin resistance, non-alcoholic fatty liver disease including non-alcoholic steatohepatitis
WO2018178722A1 (en) 2017-03-31 2018-10-04 The University Of Liverpool Prodrug compositions
CN111093632A (zh) * 2017-06-15 2020-05-01 展旺生命科技股份有限公司 活性成分粒子的制备方法
US11517013B2 (en) 2017-08-25 2022-12-06 Vive Crop Protection Inc. Multi-component, soil-applied, pesticidal compositions
WO2019166834A1 (en) 2018-03-02 2019-09-06 The University Of Liverpool Solid compositions of actives, processes for preparing same and uses of such solid compositions
JP6858729B2 (ja) * 2018-05-25 2021-04-14 ▲財▼▲団▼法人国防教育研究基金会Ｎａｔｉｏｎａｌ Ｄｅｆｅｎｓｅ Ｅｄｕｃａｔｉｏｎ Ａｎｄ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ 肝臓に対する副作用がない、新しいアセトアミノフェン複合組成
CN113164552B (zh) 2018-10-04 2025-06-06 新泽西州立罗格斯大学 使用神经介素肽减少2型细胞因子介导的炎症的方法
WO2020135600A1 (zh) * 2018-12-28 2020-07-02 南京善思生物科技有限公司 纳米农药制剂及其制备方法
CN109846821B (zh) * 2019-01-03 2021-07-06 昆药集团股份有限公司 一种蒿甲醚纳米制剂及其制备方法
WO2020186187A1 (en) 2019-03-13 2020-09-17 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods for treating bladder and urethra dysfunction and disease
CN110074993A (zh) * 2019-06-05 2019-08-02 山东大学 一种制备紫外吸收剂纳米颗粒的方法
CA3163031A1 (en) * 2019-06-28 2020-12-30 Tien Canh Le Extended release gastroretentive formulation against helicobacter pylori
WO2021062012A1 (en) 2019-09-25 2021-04-01 Emory University Use of klk10 and engineered derivatizations thereof
KR20220090524A (ko) * 2019-10-28 2022-06-29 구미아이 가가쿠 고교 가부시키가이샤 농약조성물 및 그 제조방법
CA3165922A1 (en) 2020-01-17 2021-07-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Gene therapy for treatment of crx-autosomal dominant retinopathies
US20230181672A1 (en) 2020-05-07 2023-06-15 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Aberrant post-translational modifications (ptms) in methyl- and propionic acidemia and a mutant sirtuin (sirt) to metabolize ptms
IT202000022789A1 (it) 2020-09-28 2020-12-28 Vitop Moulding Srl Rubinetto erogatore provvisto di sistema di collocamento, bloccaggio e orientamento su scatole di tipo Bag-In-Box
GB202115049D0 (en) 2021-10-20 2021-12-01 Univ Liverpool Chemical Compositions
WO2023196898A1 (en) 2022-04-07 2023-10-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Beta globin mimetic peptides and their use
CN114732009B (zh) * 2022-06-13 2022-08-23 山东百农思达生物科技有限公司 一种含有吡唑醚菌酯和烯酰吗啉的水分散粒剂的制备方法
AU2024240009A1 (en) 2023-03-17 2025-09-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for treatment of age-related macular degeneration
GB202304657D0 (en) 2023-03-29 2023-05-10 Univ Liverpool Atovaquine compositions

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB501835A (en) 1936-05-29 1939-03-02 Siemens Ag Process and apparatus for reducing the power required for the mechanical treatment of movable masses
GB1305024A (enExample) * 1969-07-10 1973-01-31
GB1554662A (en) * 1976-05-05 1979-10-24 Inverni Della Beffa Spa Polyhydroxyphenylchromanones
US4230687A (en) * 1978-05-30 1980-10-28 Griffith Laboratories U.S.A., Inc. Encapsulation of active agents as microdispersions in homogeneous natural polymeric matrices
DE3439482A1 (de) * 1984-10-27 1986-05-07 Röhm GmbH, 6100 Darmstadt Verfahren zur beschichtung von substraten mit kratzfesten, nichtreflektierenden ueberzuegen
US4830858A (en) * 1985-02-11 1989-05-16 E. R. Squibb & Sons, Inc. Spray-drying method for preparing liposomes and products produced thereby
US5160530A (en) * 1989-01-24 1992-11-03 Griffin Corporation Microencapsulated polymorphic agriculturally active material
GB8918807D0 (en) * 1989-08-17 1989-09-27 Shell Int Research A solid pesticidal formulation,a process for its preparation and the use thereof
JP3067810B2 (ja) * 1990-12-21 2000-07-24 中外製薬株式会社 経口投与用ｏ／ｗ型エマルジョンの乾燥粉末製造法
GB9304294D0 (en) * 1993-03-03 1993-04-21 Zeneca Ltd Herbicidal compositions
DE4329446A1 (de) * 1993-09-01 1995-03-02 Basf Ag Verfahren zur Herstellung von feinteiligen Farb- oder Wirkstoffzubereitungen
US5858398A (en) * 1994-11-03 1999-01-12 Isomed Inc. Microparticular pharmaceutical compositions
TW318777B (enExample) * 1995-06-29 1997-11-01 Novartis Ag
WO1997013503A1 (en) 1995-10-13 1997-04-17 The Penn State Research Foundation Synthesis of drug nanoparticles by spray drying
GB9606188D0 (en) 1996-03-23 1996-05-29 Danbiosyst Uk Pollysaccharide microspheres for the pulmonary delivery of drugs
US5858409A (en) * 1996-04-17 1999-01-12 Fmc Corporation Hydrolyzed cellulose granulations for pharmaceuticals
AU5806898A (en) * 1996-12-31 1998-07-31 Inhale Therapeutic Systems Processes and compositions for spray drying hydrophobic drugs in organic solventsuspensions of hydrophilic excipients
JP4183279B2 (ja) * 1997-04-15 2008-11-19 アール ピー シェーラー テクノロジーズ インコーポレーテッド 医薬用加水分解セルロース顆粒
WO1999044594A1 (fr) * 1998-03-05 1999-09-10 Nippon Shinyaku Co., Ltd. Emulsions huileuses destinees a etre administrees par inhalation
JPH11322587A (ja) 1998-05-18 1999-11-24 Sumitomo Chem Co Ltd 常温で固体の生理活性物質のマイクロカプセル化方法およびこの方法により得られるマイクロカプセル組成物
JP2002534371A (ja) * 1999-01-06 2002-10-15 コリア リサーチ インスティテュート オブ ケミカル テクノロジー 水不溶性薬物を含む医薬的活性成分の製造方法及びそれを含む経口投与用医薬組成物
ATE400252T1 (de) * 1999-02-10 2008-07-15 Pfizer Prod Inc Pharmazeutische feste dispersionen
GB9904012D0 (en) 1999-02-22 1999-04-14 Zeneca Ltd Agrochemical formulation
US7919119B2 (en) 1999-05-27 2011-04-05 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6610317B2 (en) * 1999-05-27 2003-08-26 Acusphere, Inc. Porous paclitaxel matrices and methods of manufacture thereof
JP4722295B2 (ja) * 1999-05-27 2011-07-13 エイカスフィアー・インコーポレーテッド 多孔性薬剤マトリクスおよびその製造方法
US6395300B1 (en) * 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
GB9915231D0 (en) * 1999-06-29 1999-09-01 Pfizer Ltd Pharmaceutical complex
GB9920148D0 (en) * 1999-08-25 1999-10-27 Smithkline Beecham Plc Novel composition
EP1246668B1 (en) * 1999-12-01 2005-11-30 Natco Pharma Limited An rapid acting freeze dired oral pharmaceutical composition for treating migraine
KR100694667B1 (ko) * 1999-12-08 2007-03-14 동아제약주식회사 생체내이용률 향상과 개인간 및 개인내 흡수 편차를감소시킨 이트라코나졸 함유 항진균성 제제
US6207674B1 (en) 1999-12-22 2001-03-27 Richard A. Smith Dextromethorphan and oxidase inhibitor for weaning patients from narcotics and anti-depressants
AU7488001A (en) * 2000-05-22 2001-12-03 Verion Inc Method for increasing the compressibility of poorly binding powder materials
US6932963B2 (en) * 2000-06-23 2005-08-23 Nicholas V. Perricone Treatment of skin wounds using polyenylphosphatidylcholine and alkanolamines
IT1318618B1 (it) 2000-07-10 2003-08-27 A C R Applied Coating Res S A Microsfere bioadesive a rilascio rapido per la somministrazionesublinguale di principi attivi.
EP1304106A4 (en) * 2000-07-24 2005-01-19 Ono Pharmaceutical Co FREEZING PREPARATION OF N-o- (p-PIVALOYLOXYBENZENESULFONYLAMINO) BENZOYL] GLYCIN MONOSODIUM SALT TETRAHYDRATE AND PROCESS FOR THE PRODUCTION THEREOF
DE10036871A1 (de) * 2000-07-28 2002-02-14 Pharmasol Gmbh Dispersionen zur Formulierung wenig oder schwer löslicher Wirkstoffe
WO2002024169A1 (en) * 2000-09-20 2002-03-28 Skyepharma Canada Inc. Spray drying process and compositions of fenofibrate
US6756062B2 (en) * 2000-11-03 2004-06-29 Board Of Regents University Of Texas System Preparation of drug particles using evaporation precipitation into aqueous solutions
US8067032B2 (en) * 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
JP2004517699A (ja) * 2001-01-30 2004-06-17 ボード オブ リージェンツ ユニバーシティ オブ テキサス システム 液体中への噴霧凍結によるナノ粒子およびミクロ粒子の製造方法
US6355675B1 (en) 2001-05-15 2002-03-12 Isp Investments Inc. Emulsifiable concentrate of a water-insoluble fungicide
DE60237087D1 (de) * 2001-06-01 2010-09-02 Pozen Inc Pharmazeutische zusammensetzungen für die koordinierte abgabe von nsaid
PL368587A1 (en) * 2001-06-22 2005-04-04 Pfizer Products Inc. Pharmaceutical compositions comprising low-solubility and/or acid-sensitive drugs and neutralized acidic polymers
KR100425226B1 (ko) * 2001-07-03 2004-03-30 주식회사 팜트리 아세클로페낙을 함유하는 경제적인 경구용 제제의 조성 및제법
EP1420582B1 (en) * 2001-08-21 2012-03-21 Sony Corporation Information processing system; information processing apparatus; and method
JP2005504090A (ja) * 2001-09-26 2005-02-10 バクスター・インターナショナル・インコーポレイテッド 分散体および溶媒相または液相の除去によるサブミクロンサイズ−ナノ粒子の調製
US20060003012A9 (en) * 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
DE10151392A1 (de) * 2001-10-18 2003-05-08 Bayer Cropscience Ag Pulverförmige Feststoff-Formulierungen
EP1465485B1 (en) * 2001-11-07 2006-04-26 Basf Aktiengesellschaft Nanoparticles comprising a crop protection agent
EP1443819A1 (en) * 2001-11-07 2004-08-11 Basf Aktiengesellschaft Solid crop protection formulations containing cinidon-ethyl, and corresponding dispersions
PL372247A1 (en) * 2002-02-01 2005-07-11 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
CA2473991C (en) * 2002-02-01 2009-09-15 Pfizer Products Inc. Controlled release pharmaceutical dosage forms of a cholesteryl ester transfer protein inhibitor
US6780324B2 (en) * 2002-03-18 2004-08-24 Labopharm, Inc. Preparation of sterile stabilized nanodispersions
US20040028505A1 (en) * 2002-06-07 2004-02-12 Bilbrey Robert A. Document tape binding system with automatic tape feed, tape indicia sensing, spine printing method and post-bind automation mechanisms
AU2003245313A1 (en) 2002-06-10 2003-12-22 Elan Pharma International, Ltd Nanoparticulate formulations comprising hmg coa reductase inhibitor derivatives (statins), novel combinations thereof as well as manufacturing of these pharmaceutical compositions
US20030017208A1 (en) * 2002-07-19 2003-01-23 Francis Ignatious Electrospun pharmaceutical compositions
DE10244681A1 (de) * 2002-09-24 2004-04-08 Boehringer Ingelheim International Gmbh Neue feste Telmisartan enthaltende pharmazeutische Formulierungen und deren Herstellung
EP1556091A1 (en) * 2002-10-04 2005-07-27 Elan Pharma International Limited Gamma irradiation of solid nanoparticulate active agents
CN1176649C (zh) 2002-10-16 2004-11-24 上海医药工业研究院 舒马普坦干粉吸入剂及其制备方法
WO2004098570A1 (en) * 2002-10-30 2004-11-18 Spherics, Inc. Nanoparticulate bioactive agents
US7332183B2 (en) * 2002-12-26 2008-02-19 Pozen Inc. Multilayer dosage forms containing NSAIDs and triptans
CA2511512C (en) * 2002-12-27 2013-10-29 Chiron Corporation Immunogenic compositions containing phospholipid
AU2004206109A1 (en) * 2003-01-21 2004-08-05 Ranbaxy Laboratories Limited Co-precipitated amorphous losartan and dosage forms comprising the same
US20040197301A1 (en) * 2003-02-18 2004-10-07 Zhong Zhao Hybrid polymers and methods of making the same
EP1594470A4 (en) * 2003-02-19 2007-10-17 Biovail Lab Int Srl QUICK ABSORPTION 5-HT SELECTIVE AGONIST FORMULATIONS
WO2004075921A1 (en) * 2003-02-26 2004-09-10 Vrije Universiteit Brussel Inclusion complex of artemisinin or derivates thereof with cyclodextrins
CA2521420A1 (en) 2003-04-08 2004-10-28 Progenics Pharmaceuticals, Inc. Combination therapy for constipation comprising a laxative and a peripheral opioid antagonist
US20040247624A1 (en) * 2003-06-05 2004-12-09 Unger Evan Charles Methods of making pharmaceutical formulations for the delivery of drugs having low aqueous solubility
CA2465565A1 (en) 2003-06-12 2004-12-12 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
EP1648515B1 (en) * 2003-07-16 2012-11-21 Boehringer Ingelheim International GmbH Chlorthalidone combinations
US7687167B2 (en) * 2003-07-18 2010-03-30 Panasonic Corporation Power supply unit
CL2004001884A1 (es) 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
DE10338403A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverformulierung, enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyrindinyl)-piperazin, Verfahren zu dessen Herstellung sowie dessen Verwendung als Inhalativum
DE10351004A1 (de) * 2003-10-30 2005-05-25 Basf Ag Nanopartikuläre Wirkstoffformulierungen
DE10351087A1 (de) * 2003-10-31 2005-05-25 Bayer Technology Services Gmbh Feste Wirkstoff-Formulierung
KR100603974B1 (ko) * 2003-12-05 2006-07-25 김갑식 고체상 지질을 용매로 이용한 나노수준의 또는 비결정질입자의 제조 방법
ATE500819T1 (de) * 2003-12-31 2011-03-15 Bend Res Inc Stabilisierte pharmazeutische feste zusammensetzungen von arzneimitteln mit geringer löslichkeit, poloxameren und stabilisierenden polymeren
KR100629771B1 (ko) * 2004-01-27 2006-09-28 씨제이 주식회사 결정성이 감소되거나 무정형화된 올티프라즈의 제조방법
IL160095A0 (en) * 2004-01-28 2004-06-20 Yissum Res Dev Co Formulations for poorly soluble drugs
JP2005298347A (ja) * 2004-04-06 2005-10-27 Yoshiaki Kawashima 吸入製剤及びその製造方法
KR100598326B1 (ko) * 2004-04-10 2006-07-10 한미약품 주식회사 ＨＭＧ-ＣｏＡ 환원효소 억제제의 경구투여용 서방형 제제및 이의 제조방법
US20070218185A1 (en) * 2004-04-28 2007-09-20 Beindorff Christiaan M Edible Oil Containing Statins
WO2005117834A1 (en) * 2004-05-27 2005-12-15 Janssen Pharmaceutica N.V. Solid dispersions of a basic drug compound and a polymer containing acidic groups
JP2008500405A (ja) 2004-06-01 2008-01-10 テバ ジョジセルジャール ザ−トケルエン ムケド レ−スベニュタ−ルシャシャ−グ 薬物の非晶質形態の調製方法
DE102004031298A1 (de) 2004-06-28 2006-01-12 Basf Ag Wässrige Dispersionen schwer wasserlöslicher oder wasserunlöslicher Wirkstoffe und daraus hergestellte Trockenpulver enthaltend mindestens ein Polyethergruppen enthaltendes Polymer als Schutzkolloid
US20070298111A1 (en) * 2004-10-01 2007-12-27 Eisai R&D Management Co., Ltd. Fine Particle-Containing Composition and Manufacturing Method Therefor
US20060105038A1 (en) * 2004-11-12 2006-05-18 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions prepared by coacervation
EP1835890A2 (en) 2005-01-06 2007-09-26 Elan Pharma International Limited Nanoparticulate candesartan formulations
GB0501835D0 (en) * 2005-01-28 2005-03-09 Unilever Plc Improvements relating to spray dried compositions
GB0613925D0 (en) * 2006-07-13 2006-08-23 Unilever Plc Improvements relating to nanodispersions
WO2008076780A2 (en) * 2006-12-14 2008-06-26 Isp Investments Inc. Amorphous valsartan and the production thereof

Also Published As

Publication number Publication date
WO2008006716A2 (en) 2008-01-17
AU2007274041A1 (en) 2008-01-17
ZA200900345B (en) 2010-05-26
BRPI0714351A2 (pt) 2013-03-19
IL195933A (en) 2013-06-27
WO2008006712A2 (en) 2008-01-17
CN101489533A (zh) 2009-07-22
US20090325995A1 (en) 2009-12-31
BRPI0714352A2 (pt) 2013-03-19
WO2008007150A1 (en) 2008-01-17
WO2008007152A3 (en) 2008-03-06
US8821932B2 (en) 2014-09-02
US20100008995A1 (en) 2010-01-14
ES2741124T3 (es) 2020-02-10
WO2008006713A3 (en) 2008-07-31
CA2657548A1 (en) 2008-01-17
CA2657586A1 (en) 2008-01-17
AU2007271831B2 (en) 2010-11-18
US20090239749A1 (en) 2009-09-24
AR061990A1 (es) 2008-08-10
AU2007271830B2 (en) 2010-11-11
US20120135058A1 (en) 2012-05-31
CA2659666A1 (en) 2008-01-17
EP2040680A2 (en) 2009-04-01
CL2007002031A1 (es) 2008-01-18
MX2009000309A (es) 2009-01-26
CA2656223A1 (en) 2008-01-17
US20100015233A1 (en) 2010-01-21
ZA200900028B (en) 2010-04-28
CN102631874A (zh) 2012-08-15
BRPI0714179A2 (pt) 2012-12-25
AU2007271827A1 (en) 2008-01-17
CN101489534A (zh) 2009-07-22
CL2010000516A1 (es) 2010-10-15
WO2008006713A2 (en) 2008-01-17
WO2008006714A2 (en) 2008-01-17
AR061992A1 (es) 2008-08-10
AU2010201900A1 (en) 2010-06-03
US20100068282A1 (en) 2010-03-18
AU2007271831A1 (en) 2008-01-17
CN101516342A (zh) 2009-08-26
EP2040678A2 (en) 2009-04-01
CN101516341A (zh) 2009-08-26
ZA200900030B (en) 2010-04-28
CA2657582A1 (en) 2008-01-17
EP2040681A2 (en) 2009-04-01
AU2007271828B2 (en) 2010-12-02
WO2008006715A2 (en) 2008-01-17
JP2009542793A (ja) 2009-12-03
CA2656233A1 (en) 2008-01-17
JP2009542795A (ja) 2009-12-03
ZA200900347B (en) 2010-04-28
CL2007002030A1 (es) 2008-01-18
US20120134940A1 (en) 2012-05-31
ZA200900027B (en) 2010-04-28
EP2386292A1 (en) 2011-11-16
AR061991A1 (es) 2008-08-10
CA2656229C (en) 2014-05-27
BRPI0714176A2 (pt) 2012-12-25
US7691873B2 (en) 2010-04-06
CL2007002032A1 (es) 2008-01-18
MX2009000307A (es) 2009-01-26
JP2009542762A (ja) 2009-12-03
WO2008006712A3 (en) 2009-02-26
AR077195A2 (es) 2011-08-10
WO2008006714A3 (en) 2008-02-21
CN101489531A (zh) 2009-07-22
BRPI0714230A2 (pt) 2013-01-15
WO2008006716A3 (en) 2008-03-13
EP2040681B1 (en) 2017-08-09
US9060937B2 (en) 2015-06-23
CN101516340A (zh) 2009-08-26
JP2009542761A (ja) 2009-12-03
BRPI0722376A2 (pt) 2012-05-22
JP2009542764A (ja) 2009-12-03
IL195911A0 (en) 2009-09-01
TW200812694A (en) 2008-03-16
EP2040679A2 (en) 2009-04-01
AU2007274039A1 (en) 2008-01-17
JP2009542763A (ja) 2009-12-03
WO2008006715A3 (en) 2008-05-08
EP2040677B1 (en) 2019-05-08
JP2009542794A (ja) 2009-12-03
EP2269581A1 (en) 2011-01-05
CA2656229A1 (en) 2008-01-17
ZA200900029B (en) 2010-04-28
EP2040680B1 (en) 2019-08-07
JP2009542760A (ja) 2009-12-03
AU2007271829B2 (en) 2011-10-27
EP2040677A2 (en) 2009-04-01
US8945626B2 (en) 2015-02-03
US20090304806A1 (en) 2009-12-10
AU2007271830A1 (en) 2008-01-17
AU2007271828A1 (en) 2008-01-17
CN101489532A (zh) 2009-07-22
WO2008007152A2 (en) 2008-01-17
EP2387992A1 (en) 2011-11-23
CA2656217A1 (en) 2008-01-17
CN101849911A (zh) 2010-10-06
WO2008007151A3 (en) 2008-03-06
ES2752460T3 (es) 2020-04-06
BRPI0714353A2 (pt) 2013-05-07
US20090175953A1 (en) 2009-07-09
ZA200900031B (en) 2010-04-28
AU2007271829A1 (en) 2008-01-17
CN101489535A (zh) 2009-07-22
AU2007271827B2 (en) 2010-10-14
WO2008007151A2 (en) 2008-01-17
IL195933A0 (en) 2009-09-01
US20100015229A1 (en) 2010-01-21
GB0613925D0 (en) 2006-08-23
BRPI0714177A2 (pt) 2011-05-03
JP2010202665A (ja) 2010-09-16
CN102671585A (zh) 2012-09-19
AU2007274040A1 (en) 2008-01-17

Similar Documents

Publication Publication Date Title
AP2008004713A0 (en) Improvements relating to anti-parasetic compositions
GB0623838D0 (en) Novel compositions
GB0712988D0 (en) Improvements in or relating to compositions
GB0719161D0 (en) Improvements relating to fabrick treatment compositions
EP2219637A4 (en) AVENANTHRAMIDE COMPOSITIONS
GB0711683D0 (en) Compositions
GB0712024D0 (en) Compositions
GB0607085D0 (en) Novel compositions
GB0625069D0 (en) Compositions
ZA201002504B (en) Novel taxoid-based compositions
GB0715605D0 (en) Improvements in or relating to compositions
GB0620279D0 (en) Compositions
GB0618657D0 (en) Compositions
ZA200901574B (en) Topical compositions
GB0620918D0 (en) Compositions
GB0714811D0 (en) Improvements in or relating to compositions
GB0917779D0 (en) Novel compositions
GB0601899D0 (en) Compositions
GB0611033D0 (en) Compositions
GB0603914D0 (en) Improvement in or relating to compositions
GB0611069D0 (en) Improvements in or relating to compositions
GB0610168D0 (en) Improvements in or relating to compositions
GB0602109D0 (en) Improvements in or relating to compositions
GB0621751D0 (en) Compositions
GB0620204D0 (en) Compositions